<SUBMISSION>
<ACCESSION-NUMBER>0001104659-06-007963
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20060212
<ITEMS>1.01
<ITEMS>1.02
<ITEMS>9.01
<FILING-DATE>20060213
<DATE-OF-FILING-DATE-CHANGE>20060213
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>CERUS CORP
<CIK>0001020214
<ASSIGNED-SIC>2836
<IRS-NUMBER>680262011
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-21937
<FILM-NUMBER>06600787
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>2411 STANWELL DR
<CITY>CONCORD
<STATE>CA
<ZIP>94520
<PHONE>9252886000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>2525 STANWELL DRIVE
<STREET2>STE 300
<CITY>CONCORD
<STATE>CA
<ZIP>94520
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>CERUS TECHNOLOGIES INC
<DATE-CHANGED>19960731
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a06-4923_18k.htm
<DESCRIPTION>CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border:none;border-top:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p align="left" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington,
D.C. 20549</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM 8-K</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT<br>
Pursuant to Section 13 or 15(d) of the<br>
Securities Exchange Act of 1934</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report
(Date of earliest event reported):&#160; <b><font style="font-weight:bold;">February 12, 2006</font></b></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CERUS CORPORATION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of
registrant as specified in its charter)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-21937</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">68-0262011</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other Jurisdiction<br>
  of Incorporation)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File
  Number)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer
  Identification No.)</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2411
  Stanwell Drive</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Concord,
  California 94520</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of
  principal executive offices and zip code)</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s
  telephone number, including area code: <b><font style="font-weight:bold;">(925) 288-6000</font></b></font></p>
  </td>
 </tr>
</table>

</div>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-align:left;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160; Written communications pursuant to
Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>

<p align="left" style="margin:0in 0in .0001pt .25in;text-align:left;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-align:left;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160; Soliciting material pursuant to
Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p align="left" style="margin:0in 0in .0001pt .25in;text-align:left;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-align:left;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160; Pre-commencement communications pursuant to
Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p align="left" style="margin:0in 0in .0001pt .25in;text-align:left;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-align:left;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160; Pre-commencement communications pursuant to
Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<div style="border:none;border-bottom:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="2" width="100%" noshade color="gray" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\arahim\06-4923-1\task812747\4923-1-ba.htm',USER='agarahim',CD='Feb 13 08:04 2006' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.01 Entry into a Material Definitive Agreement.</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On February 12, 2006, Cerus Corporation (&#147;Cerus&#148;) entered into a
Commercialization Transition Agreement (the &#147;Agreement&#148;) with certain
subsidiaries of Baxter International Inc. (&#147;Baxter&#148;) pursuant to which Cerus
has obtained exclusive worldwide commercial rights to market, distribute and
sell the INTERCEPT Blood System for platelets and plasma, other than in certain
Asian countries in which rights have previously been granted to BioOne
Corporation. Cerus currently has exclusive worldwide commercial rights to
market the INTERCEPT Blood System for red blood cells.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As part of the transfer of commercialization rights to Cerus, Baxter has
agreed to supply at Cerus&#146; expense until December 31, 2006, certain transition
services, including regulatory, technical and back-office support. Cerus agreed
to purchase UVA illumination devices from Baxter and may purchase other
finished goods and work in process from Baxter&#146;s inventory for use with the
platelet and plasma systems. Baxter has agreed to manufacture systems and
components for the platelet and plasma systems on a cost-plus basis through December
31, 2008. Baxter has agreed to supply only very limited types of components for
the prototype of the red blood cell system.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In return, Cerus is obligated to pay Baxter royalties on future INTERCEPT
Blood System product sales at royalty rates that vary by product, with a rate
of 10% of net sales for the platelet system, 3% for the plasma system and 5%
for the red blood cells system.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the Agreement, Cerus will record gains in excess of
$6.5 million, largely from disbursements made by Baxter to us from the escrow
account established in the 2005 Restructuring Agreements (as defined below) allocated
to support sales and marketing expenses in Europe through 2006. The majority of
the disbursed funds must be spent on certain specified European activities
associated with the commercialization of the INTERCEPT Blood System for
platelets and plasma, and any such funds that remain unspent by the end of 2006
will be split evenly between Cerus and Baxter. Cerus will also repay a
promissory note in the principal amount of $4.5 million, plus accrued interest,
held by Baxter Capital Corporation, a subsidiary of Baxter, that was to mature
in December 2006.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Agreement amends and supersedes portions of the Restructuring
Agreement, License Agreement, Manufacturing and Supply Agreement, Transition
Services Agreement, and Trademark License Agreement (collectively, the &#147;2005 Restructuring
Agreements&#148;) entered into between Cerus and Baxter in February 2005. The
Agreement also terminates the prior Development Manufacturing and Marketing
Agreement dated December 10, 1993, as amended, and the Development,
Manufacturing and Marketing Agreement dated April 1, 1996, as amended, between
the parties.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A copy of the joint press release issued by Cerus and Baxter, entitled &#147;Cerus
Obtains Exclusive Rights to INTERCEPT Blood System from Baxter,&#148; announcing and
briefly</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="2" width="100%" noshade color="gray" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\arahim\06-4923-1\task812747\4923-1-ba.htm',USER='agarahim',CD='Feb 13 08:04 2006' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">describing the agreement is filed as Exhibit 99.1 hereto and is
incorporated herein by reference.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.02 Termination of a Material Definitive
Agreement.</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reference is made to Item 1.01 regarding the termination of the
Development Manufacturing and Marketing Agreement dated December 10, 1993, as
amended, and the Development, Manufacturing and Marketing Agreement dated April
1, 1996 between the parties, as amended</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
9.01.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Financial Statements
and Exhibits.</b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Exhibits</b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Press
Release, dated February 13, 2006, entitled &#147;Cerus Obtains Exclusive Rights to
INTERCEPT Blood System from Baxter.&#148;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="2" width="100%" noshade color="gray" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\arahim\06-4923-1\task812747\4923-1-ba.htm',USER='agarahim',CD='Feb 13 08:04 2006' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURE</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.</font></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="348" valign="top" style="padding:0in 0in 0in 0in;width:261.0pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="372" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:279.0pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERUS
  CORPORATION</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="348" valign="top" style="padding:0in 0in 0in 0in;width:261.0pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="372" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:279.0pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="348" valign="top" style="padding:0in 0in 0in 0in;width:261.0pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="372" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:279.0pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="348" valign="top" style="padding:0in 0in 0in 0in;width:261.0pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:&nbsp;&nbsp;February
  13, 2006</font></p>
  </td>
  <td width="25" valign="top" style="padding:0in 0in 0in 0in;width:18.9pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="116" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:86.85pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Howard G.
  Ervin</font></p>
  </td>
  <td width="231" valign="top" style="padding:0in 0in 0in 0in;width:173.25pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="348" valign="top" style="padding:0in 0in 0in 0in;width:261.0pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="25" valign="top" style="padding:0in 0in 0in 0in;width:18.9pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="347" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:260.1pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Howard G. Ervin</font></p>
  </td>
 </tr>
 <tr>
  <td width="348" valign="top" style="padding:0in 0in 0in 0in;width:261.0pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="25" valign="top" style="padding:0in 0in 0in 0in;width:18.9pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="347" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:260.1pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President,
  Legal Affairs</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="2" width="100%" noshade color="gray" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\arahim\06-4923-1\task812747\4923-1-ba.htm',USER='agarahim',CD='Feb 13 08:04 2006' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT INDEX</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="721" style="border-collapse:collapse;margin-left:.7pt;width:540.7pt;">
 <tr>
  <td width="46" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:34.4pt;">
  <p style="margin:0in 0in .0001pt;text-align:justify;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number</font></b></p>
  </td>
  <td width="25" valign="bottom" style="padding:0in 0in 0in 0in;width:18.9pt;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="650" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:487.4pt;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="46" valign="top" style="border:none;padding:0in 0in 0in 0in;width:34.4pt;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="25" valign="bottom" style="padding:0in 0in 0in 0in;width:18.9pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="650" valign="top" style="border:none;padding:0in 0in 0in 0in;width:487.4pt;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release,
  dated February 13, 2006, entitled &#147;Cerus Obtains Exclusive Rights to
  INTERCEPT Blood System from Baxter.&#148;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><hr size="2" width="100%" noshade color="gray" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\arahim\06-4923-1\task812747\4923-1-ba.htm',USER='agarahim',CD='Feb 13 08:04 2006' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a06-4923_1ex99d1.htm
<DESCRIPTION>EXHIBIT 99
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="720" valign="top" style="padding:0in 0in 0in 0in;width:7.5in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="151" height="36" src="g49231mmi001.gif"></font></p>
  </td>
  <td width="720" valign="top" style="padding:0in 0in 0in 0in;width:7.5in;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="123" height="28" src="g49231mmi002.jpg"></font></p>
  </td>
 </tr>
</table>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">FOR IMMEDIATE RELEASE</font></u></p>

<p style="color:#3E6097;margin:0in 0in .0001pt;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="color:#3E6097;margin:0in 0in .0001pt;text-align:center;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">Cerus Obtains Exclusive Rights to INTERCEPT Blood
System from Baxter</font></p>

<p align="center" style="color:#3E6097;margin:0in 0in .0001pt;text-align:center;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONCORD, Calif., and DEERFIELD, Ill., February 13,
2006 &#150; Cerus Corporation (NASDAQ: CERS) and subsidiaries of Baxter
International Inc. (NYSE:BAX) today announced that they have entered into a
definitive agreement for Cerus to obtain Baxter&#146;s remaining commercial rights
to the INTERCEPT</font><font face="Symbol">&#228;</font><font face="Times New Roman"> Blood System for platelets and plasma effective
February 1, 2006.</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus now has exclusive rights to the INTERCEPT Blood
System for all three commonly transfused components: platelets, plasma and red
blood cells, excluding rights in certain Asian countries for platelets and
plasma.</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Cerus is now positioned to deliver on a new standard
of blood safety with the INTERCEPT Blood System,&#148; said Claes Glassell,
president and CEO of Cerus. &#147;We strongly believe pathogen inactivation will
have a significant impact on blood safety globally. We look forward to applying
our expertise and focus to successfully commercializing the INTERCEPT Blood
System.&#148;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We believe that Cerus is in a good position to assume
lead responsibility for the commercialization of the INTERCEPT Blood System on
a global basis,&#148; said Kevin McCulloch, general manager for Baxter&#146;s Transfusion
Therapies business. &#147;Consistent with our long-standing support for ensuring an
adequate supply of the safest blood products possible, we will work closely
with Cerus and our customers to ensure a smooth transition of responsibilities.&#148;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the agreement:</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Cerus has obtained
exclusive commercial rights to market INTERCEPT Blood System for platelets and
plasma worldwide, except in certain Asian countries in which rights have
previously been granted to BioOne Corporation.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Baxter will provide
technical service, clinical education and select regulatory activities in
Europe through 2006.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Baxter will continue manufacturing
responsibilities in support of Cerus&#146; development and commercialization
activities for the platelet system and plasma system through 2008.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Cerus will pay Baxter royalties based on future
sales of INTERCEPT Blood System for platelets and plasma. These royalty
provisions replace the previous agreement where Cerus received a sharing of
gross profit from Baxter sales.</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This restructuring does not affect the relationship
with the companies&#146; Asian partner, BioOne Corporation. BioOne continues to
maintain the commercial rights to market and distribute INTERCEPT Blood System
for platelets and plasma in Japan, China, Taiwan, South Korea, Thailand, Vietnam
and Singapore, following receipt of regulatory approval in each of those
countries.</font></p>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<div style="margin:0in 0in .0001pt;"><hr size="2" width="100%" noshade color="gray" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\tvenkatesh\06-4923-1\task812715\4923-1-mm.htm',USER='tbose',CD='Feb 13 06:36 2006' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<h5 style="font-weight:bold;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONFERENCE CALL AND FORM 8-K FILING</font></b></h5>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus Management will hold a conference call
at 8:00 am PST today to discuss the agreement, including financial details.
Additional information will be contained in a form 8-K filing, being filed with
the Securities and Exchange Commission, which may also be found in the investor
relations section on www.cerus.com. Interested parties may also access a live
Internet broadcast at http://phx.corporate-ir.net/playerlink.zhtml?c=61076&amp;s=wm&amp;e=1212331.
For those unable to listen to the live broadcast, the call will be archived
temporarily at www.cerus.com</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>

<h5 style="font-weight:bold;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">ABOUT THE INTERCEPT BLOOD SYSTEM</font></b></h5>

<h5 style="font-weight:bold;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></h5>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The INTERCEPT Blood System is designed to reduce the
risk of transfusion-transmitted diseases by inactivating certain pathogens that
may be present in donated blood components.</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The INTERCEPT Blood System is approved for use in
Europe for platelets, and has been implemented by blood centers in several European
countries. A CE mark application has been filed for the INTERCEPT Blood System
for plasma and three Phase III trials in the United States have been completed.
Phase III trials of the INTERCEPT Blood System for red blood cells were halted
in 2003 after antibody reactivity was observed in two patients. Based on the
development of a modified process that may diminish the likelihood of antibody
reactivity with treated red cells, re-entry into clinical trials is planned.</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font face="Times New Roman">&nbsp;</font></p>

<h5 style="font-weight:bold;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">ABOUT CERUS</font></b></h5>

<h5 style="font-weight:bold;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></h5>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus Corporation is developing novel products for
cancer, infectious disease and blood safety based on multiple, innovative
technology platforms. The company is building a pipeline of next generation
cancer immunotherapies by combining its proprietary attenuated Listeria vector
platform with promising disease antigens. These products are designed to
stimulate innate and T cell immune pathways, generating highly potent
anti-tumor responses. The company&#146;s KBMA vaccine technology has potential broad
applications against multiple pathogens. Cerus is applying its Helinx
technology to develop the INTERCEPT Blood System, which is designed to enhance
the safety of blood components through pathogen inactivation. The company&#146;s
strategy is to leverage the broad potential of its technologies and products
both on its own and through alliances. Cerus&#146; collaborators include MedImmune
and investigators at The Johns Hopkins University for cancer immunotherapy and
BioOne for the INTERCEPT Blood System.</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font face="Times New Roman">&nbsp;</font></p>

<h6 style="font-weight:bold;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">ABOUT BAXTER</font></b></h6>

<h6 style="font-weight:bold;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></h6>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Baxter International Inc., through its subsidiaries,
assists health-care professionals and their patients with the treatment of
complex medical conditions, including cancer, hemophilia, immune disorders,
kidney disease and trauma. The company applies its expertise in medical
devices, pharmaceuticals and biotechnology to make a meaningful difference in
patients&#146; lives.</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><em><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">Statements in this news release regarding fulfilment
of contractual commitments under the agreement, as well as statements
concerning potential efficacy and safety of products, potential regulatory
approvals, product development, royalty payments and commercialization are
forward-looking statements that involve risks and</font></i></em></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><em><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:normal;">&nbsp;</font></i></em></p>

<div style="margin:0in 0in .0001pt;"><hr size="2" width="100%" noshade color="gray" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\tvenkatesh\06-4923-1\task812715\4923-1-mm.htm',USER='tbose',CD='Feb 13 06:36 2006' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><em><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:normal;">&nbsp;</font></i></em></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><em><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">uncertainties</font></i></em><em><i><font face="Times New Roman">. Actual results could differ materially from the above forward-looking
statements as a result of certain factors, including the risks and
uncertainties related to the timing and results of clinical trials and other
development activities, the acceptability of any data by regulatory
authorities, actions by regulatory authorities and other government
authorities, including the FDA and foreign counterparts, at any stage of the
development or marketing process, technological advances in the medical field,
additional financing activities, manufacturing, product demand and market
acceptance and adoption of any products, competitive conditions, internal and
external factors that could impact commercialization and other factors
discussed in each company&#146;s filings with the Securities and Exchange
Commission. The companies do not undertake any obligation to update any
forward-looking statements as a result of new information, future events, changed assumptions or otherwise; all forward-looking
statements speak only as of the time when made. Actual results or experience
could differ materially from the forward-looking statements.</font></i></em></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><em><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">###</font></i></em></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="527" valign="top" style="padding:0in 0in 0in 0in;width:395.1pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contacts:</font></p>
  </td>
  <td width="193" valign="top" style="padding:0in 0in 0in 0in;width:144.9pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="527" valign="top" style="padding:0in 0in 0in 0in;width:395.1pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="193" valign="top" style="padding:0in 0in 0in 0in;width:144.9pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="527" valign="top" style="padding:0in 0in 0in 0in;width:395.1pt;">
  <h2 style="font-weight:normal;margin:0in 0in .0001pt;page-break-after:auto;text-decoration:underline;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus</font></u></h2>
  </td>
  <td width="193" valign="top" style="padding:0in 0in 0in 0in;width:144.9pt;">
  <h2 style="font-weight:normal;margin:0in 0in .0001pt;page-break-after:auto;text-decoration:underline;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Baxter</font></u></h2>
  </td>
 </tr>
 <tr>
  <td width="527" valign="top" style="padding:0in 0in 0in 0in;width:395.1pt;">
  <h3 style="font-weight:normal;margin:0in 0in .0001pt;page-break-after:auto;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Corporate
  Communications:</font></i></h3>
  </td>
  <td width="193" valign="top" style="padding:0in 0in 0in 0in;width:144.9pt;">
  <h3 style="font-weight:normal;margin:0in 0in .0001pt;page-break-after:auto;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Media:</font></i></h3>
  </td>
 </tr>
 <tr>
  <td width="527" valign="top" style="padding:0in 0in 0in 0in;width:395.1pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ruey-Li Hwang</font></p>
  </td>
  <td width="193" valign="top" style="padding:0in 0in 0in 0in;width:144.9pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jerreau Beaudoin</font></p>
  </td>
 </tr>
 <tr>
  <td width="527" valign="top" style="padding:0in 0in 0in 0in;width:395.1pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(925) 288-6017</font></p>
  </td>
  <td width="193" valign="top" style="padding:0in 0in 0in 0in;width:144.9pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(847) 948-3425</font></p>
  </td>
 </tr>
 <tr>
  <td width="527" valign="top" style="padding:0in 0in 0in 0in;width:395.1pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="193" valign="top" style="padding:0in 0in 0in 0in;width:144.9pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="527" valign="top" style="padding:0in 0in 0in 0in;width:395.1pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="193" valign="top" style="padding:0in 0in 0in 0in;width:144.9pt;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Investor
  Relations:</font></i></p>
  </td>
 </tr>
 <tr>
  <td width="527" valign="top" style="padding:0in 0in 0in 0in;width:395.1pt;">
  <p style="margin:0in 0in .0001pt;page-break-after:auto;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="193" valign="top" style="padding:0in 0in 0in 0in;width:144.9pt;">
  <p style="margin:0in 0in .0001pt;page-break-after:auto;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mary Kay Ladone</font></p>
  </td>
 </tr>
 <tr>
  <td width="527" valign="top" style="padding:0in 0in 0in 0in;width:395.1pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="193" valign="top" style="padding:0in 0in 0in 0in;width:144.9pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(847) 948-3371</font></p>
  </td>
 </tr>
</table>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<div style="margin:0in 0in .0001pt;"><hr size="2" width="100%" noshade color="gray" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\tvenkatesh\06-4923-1\task812715\4923-1-mm.htm',USER='tbose',CD='Feb 13 06:36 2006' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g49231mmi001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g49231mmi001.gif
M1TE&.#EAEP`D`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+!H```!D`",`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/#%NUNG*%14E!@K"U(GC-X;66!5<FC"939<V#-6\.1,G'
ME""1#4VQ"!``RA5!)(D&8,%BY;5.R)`](Y5,*E6K59%U@B9PJ5>F/PLF96HR
MX=@25VH*&LJT)%&F"X>FQ3DT0,IHQXXAT\MWKU^^QYX)#"MP#]N48HF:8C@4
ML4"V!@658)&P5>.%@@(XA=KI6.?/6CV+WHIP[5*=;ALRK0F9;L*AIU0[Y=KP
M6C28.(E>2:R9<6^5)7X?W'TP,W&&<SLN-2%VJ,Z#1&5F9N'8X/.N31T2YGCE
M-,',`53__Y8<X+C#U`ZO8T0_D+U"IK&QVX4H%^3#[MEW$A5?,XI7\PLM59U]
M[Y5%D'L)E5!"3FP)&!)1`];V##041@.-A1A>2"$T$RH474'@\4>095ZAM5`K
M#D;TE%8L<M9BB[055YY!""*T6DSX>;480JT$%R%#>.D53%['#"ED7L@,&>.(
MW0$XV'Z^70<>4S/F9B!$3SV3##2E;,B*E]`D,]625,*%4(W0"6=0F57&5!^!
M![%@@IH@?AA7>`J9]F9!5,)I)9WM.<?8@B?Z-]1P$/H9V5*4R5C"CWSB>2(+
MDSG9RISY*:J?F2!>IA"*3I8VU!YQCMI0*Y!2U-UDT+&:9YNIJK1$%*G0>9HG
M8M%@DZM`N!FTZYF,TIBBC9*.E.>AI7D5*S;9X175L]!&&]62:P9@XHBMR7@<
MB@HU^>E7.RXZ$%3!L%@NN>9J12V.P1+$2G"9"C12F[(2RFYRW0Y5Z4^HNM5H
MD-(&G)=@"W7GW4`D3O834K;*JQ1)(C%,[XEKU:64M4<-Q%6N+>7*,38=7[,N
HCV-1)]-(5YA`:<9GEL262<N>JNG,--=L\\TXYZSSSCSW['-#`0$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g49231mmi002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g49231mmi002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``<`'L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V7Q?J1TCP
MAJU\KLCQ6S[&4X(8C"D?B17SKI?B7QGK&J6VG6GB'46N;EQ&@:Y8#)]?05Z[
M\:M1^R>!UM0V&O+E$QZJN6/\A7BOA/5KS0=>BU6QT[[=/`K;8RC,%W#&3M^I
MKV<!2_<2G:[Z7.+$2_>)7.@\3R>/_",ELFJ^(;P&Y#&/R;UF^[C.>F.HKU3X
M2^(-2U_PG+)JDS3RV]P85G?[SK@'D]R,]:\3\9>+-0\7ZM#/J-O%:/!'Y(B4
M,`O.23GG/^%>FWGA[PWH?P\TG1=<\2&S264W;R6G)N&([<$[0".<=A58B"=*
M,9JTGV0J<K3;B]%W/6]R^H_.@$'H0:^>IM+^&*J=OBS6&('`",<_^.5S'@W4
M-0LO&6E/83RB1[I(RNXX=68`J1Z8KF67\T6U)Z=U8U>(LTFOQ/JII8U)#2("
M.Q84JNCC*,K#U!S7C?QO\,X%MXDME(Z6]UC_`,<;^8_*N-\#^/-2\+65_IUA
M9F[GO67[,IR=DO3.!RV1CCU`J(8'VE+VD)7?8<J_+/EDCZ3>X@C<(\T:L3@!
MF`->1ZI\;Y+;5KFRLM$CE6*9H4EDN<;\-C.`O&?K5S0?!;^'].U'QEXHD%WK
MBPR7*K(=RP,%)'L6[>@Z"O(/"NC?\))XJL-,E9PES+^]9#\P4`LQ'O@&ML-A
MJ+YG)\R7],BK5GHEHV?55M?VUQL1;JW>8KDI'*&Y[XH;4[!'*-?6RLIP095!
M!_.O,=9\$:)\.?#FJZ]I4UY]N^RM;0O+(#M,A"Y&`.:\B\+Z=H^IZ]'#KM_]
MBL"K-+/N`8G'`!(/)-9TL'"I%SC)V7D5*M*+46M3ZK&I6#$!;VV)/``E7_&G
MW%[:V>W[3<PP;ON^;(%S],U\H^*;'1+#7I;?P_>->:>J*5F8@DL1R,@#I6UX
MXU6YU#1/"=K>.9)H=-\UR_).]B%)]]J+5_V<FXVEH_(GZSO=;'T@VJZ<L*S-
M?VHB8E5<S+M)'4`YJQ'-%-&)(I$=#T96!!_&OGGPA\+;SQ?X>AU"355M;8.Z
M0Q&$OC!Y(Y`&3G\J]R\+Z*/#WAG3])WK(;6((SJ,!FZD_F37+B*-.EI&5W?L
M;4YRGJU9'D'QRU9;C6M/TM&_X](VDD'^T^,?H/UIOPB\2>'?#5EJ<NK:C';7
M-Q(BHK(Q.Q0>>`>['\J]#U?X6>&]<U:YU.^%Z]S<-N<BX('3``'8`"J7_"E_
M"'_/.]_\"37;&K1>'5%W_#U,'"?M.=6/#/%>I)K7BW5+^W8R17%RQB.,;ESA
M>/H!6K\18Y[7Q';:;,6_T#3[:W4'VC!./Q)KVC3OA+X3TV_AO([2>62%@Z+-
M.67(Z$CO6KXB\#>'_%,\=QJED7N$78)8Y"C;?0XZ_C5O'4XSBDG9(GV$G%N^
MIY-)#X(LOA.LJ_V;<:^]L.K`S"1FYXSD;0?TK#^%&G_;_B'IY(REL'N&_!<#
M]2*]AA^$O@Z&&:,::[^:H4L\[E@,@\'/'2KNC_#SP]H,UQ-ID$]O+/"8'=;A
M\[203@YX/`Y%0\7!0G%7;??S^92HR<DW;0YKXD>,(KQ)?!NBVHU+4[S]U*JC
M<L/?_OH=?1>IKQ!TU#PYKVU@8-0L)_7[KJ?U'\Q7U!H'@W0?#,LTVEV(BFFX
M>5W9W(],L215;5_A[X8US4Y=1U#31+=2@!W$KKG`P.`0.@J,/BZ5'W$G;\6Q
MU*,Y^]?4P/&^OC6?@U/JMD/DNXH@X'.S+@.#]#D5Y?\`"G4M)TGQE]MU>\CM
M8X[9Q$\GW2YP,9[<9KW_`$WPOH^DZ/+I%I9J-/F+%X)&9U.[K]XGK6+_`,*K
M\%9_Y`<?_?Z3_P"*J*6)I0IRI-.S*G2G*2EV.4^+7B*QUKP-&=(NTN[<7Z1S
M2Q<JI",P!/Y5P'@&S\'73WQ\6W8A"A/LZL[(&Z[CE?PKZ`MO!_A^TT2;1H=+
MA&G3MOD@.6#-QSDG.>!^59@^%_@L?\P&#_OX_P#\53I8NE"DZ:NO-6N*5&4I
M*6AQL&C_``>FGC@BN8II9&"(@GF)9B<`#%><?$&:%_&VH0VZA+:S*VD2`Y"K
M&H7'Y@U]`V7P]\)Z=>PWEIHL$5Q`X>-PS':PZ'DU'+\-O!\\LDLNAP/)(Q9V
M9W)8GDD\U5+&4Z<^9N3]0G0E)6T19\":?_9G@;1K4C#"V5V'NWS']370TR*)
:((4BC7;&BA57T`X%/KS9RYI.7<Z8JRL?_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
